Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes - Wikidata - awgldk - TriplyDB

Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes

Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes

http://www.wikidata.org/entity/Q36902065

about

Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease Proteomic profile in glomeruli of type-2 diabetic KKAy mice using 2-dimensional differential gel electrophoresis.Effects of three commonly-used diuretics on the urinary proteome.Epigenetic profiles of pre-diabetes transitioning to type 2 diabetes and nephropathy.Integrative Biology of Diabetic Kidney Disease Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases Urinary Microvesicle-Bound Uromodulin: A Potential Molecular Biomarker in Diabetic Kidney Disease.How to find a prognostic biomarker for progressive diabetic nephropathy.Direct determination of urinary creatinine by reactive-thermal desorption-extractive electrospray-ion mobility-tandem mass spectrometry.Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes.The role of novel biomarkers in predicting diabetic nephropathy: a review.Urinary Proteomics for Diagnosis and Monitoring of Diabetic Nephropathy.Urine AQP5 is a potential novel biomarker of diabetic nephropathy.Sustained treatment of sickle cell mice with haptoglobin increases HO-1 and H-ferritin expression and decreases iron deposition in the kidney without improvement in kidney function.Biomarkers of diabetic nephropathy: A 2017 update.The Promise of Systems Biology for Diabetic Kidney Disease.Genetic markers for urine haptoglobin is associated with decline in renal function in type 2 diabetes in East Asians.Urinary Proteome Analysis Identified Neprilysin and VCAM as Proteins Involved in Diabetic Nephropathy.

P2860

Q26747131-24F3339E-985C-4B8D-B2E5-5BBD7A96783A Q34783098-9014CBEB-A370-4480-985B-1B03A677005B Q35543587-1317B349-20F9-457E-9107-8892872F600B Q35932565-B87F5477-DBC5-4329-ACDD-4D65589CDC3B Q36623841-1DD6B3C0-965A-4DA0-8F66-C42F9B4657A4 Q37107248-1C91837A-A400-4DAF-B6F1-30B44FE0E0B0 Q37611255-F964C634-8305-4CEC-8AB7-621271B30C74 Q37715627-3956D1C7-F9C2-4A55-9AA9-C7E6DBE6DF3A Q38271670-57F06C95-252A-4184-96C4-759C0C096A16 Q38553932-43679A93-25A3-4AAB-A09A-9C82E736C559 Q38598929-03595B23-59F8-47F3-93F2-B8167A0B1332 Q38961899-1E48B63B-291B-4547-9A97-7ECA2FA34419 Q39831322-49D7C01C-BA87-4EC9-80FC-F62F73796119 Q42760191-EB449CF4-CF5D-4EF1-BFA3-65D8705CC072 Q49686004-CE2DCA16-E019-439E-881C-04350F1E2C57 Q52341285-6514AAED-6094-49C9-8860-F87F1AA9AAC5 Q52639416-14C3A421-C1D7-4275-A585-F6A57F031297 Q55084015-1EE26037-A295-4FCB-9E7F-DB8BECAB8143

P2860

Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes

http://www.wikidata.org/entity/Q36902065

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Urine haptoglobin levels predi ...... patients with type 2 diabetes

@en

type

label

Urine haptoglobin levels predi ...... patients with type 2 diabetes

@en

prefLabel

Urine haptoglobin levels predi ...... patients with type 2 diabetes

@en

P1433

Q36902065-46909C65-A912-47E5-872B-3ABADCAE5394

P1476

Q36902065-8DA28108-4A93-4270-A2A1-F450E28B5059

P2093

Q36902065-35D4E2E5-39C7-42CA-8E47-B56D9C5B5FCB

Q36902065-46D06681-1EAE-4F97-8EF7-9FCCEECCBE73

Q36902065-62BDBA7E-A850-4F87-B7FE-3BD994DAECDD

Q36902065-85641D63-A95A-4B2B-BD6D-4EDA428C6BC3

Q36902065-B214D6B4-E5D5-4891-BCC5-4CFED7E3BEC7

Q36902065-FDADA433-12D6-440F-96DD-FD402C5B857C

P2860

Q36902065-0D2FE4EB-7076-42E0-97F2-FCB0E084A52D

Q36902065-2A3D5F64-50F2-4194-9011-B9DD8397D936

Q36902065-2A4BAFEC-5C2D-4A4E-BDFC-739A2C78D859

Q36902065-2FF22F68-3830-4587-BCAB-61EE9D592D58

Q36902065-3768BA9D-8E8B-4E61-BE34-1ED1F5BA4CC7

Q36902065-439D8710-1DBE-4F01-9F5C-F6A7F929C525

Q36902065-54415FDB-7CF5-4BD1-B815-419CB7963F2C

Q36902065-59891774-D354-4D71-B4E5-953D818D38E0

Q36902065-5B331583-F2D4-4AA3-9C9C-8252C5E24ECF

Q36902065-6130630E-45FE-4CC7-B24B-1D617FB9C865

P2888

Q36902065-E6EE406F-D527-4766-AEEC-10F6E321B947

P304

Q36902065-FD996A7A-2657-4C10-9750-F13D1FB2861B

P31

Q36902065-B598459D-84F9-410C-9F66-5C16CFB08E06

P356

Q36902065-E2F4D596-FD8B-451F-9CF4-EADA5A4EFAD2

P407

Q36902065-94B37B5C-DEA8-453B-8449-FF3705CF6B94

P433

Q36902065-453965A4-003E-4ABF-9B58-C4A00562862D

P478

Q36902065-FD4D6572-6844-49B1-8B0F-98E49CDD8337

P50

Q36902065-8AEBDED4-56F9-46B6-8904-0C38369C7540

Q36902065-B9AA48A6-4A44-4818-93B9-5E8DB429892B

Q36902065-ED73C3A0-E8F0-468B-BE82-DCCAE6F095ED

Q36902065-F48A5177-D06F-4A95-A30A-F762E7C03023

P577

Q36902065-AD97FFCE-AD74-474E-B4D5-C53339B83212

P5875

Q36902065-36341068-C770-4485-9902-376425AD520A

P698

Q36902065-0B5FBE35-7D52-454D-831C-9EA0A0E51565

P921

Q36902065-87C8287F-B528-4A8F-A64C-EF78424C6B50

P932

Q36902065-F32B0D24-6739-4473-BD19-CDE85B61AFED

P356

P1433

Kidney International

P1476

Urine haptoglobin levels predi ...... patients with type 2 diabetes

@en

P2093

J Michael Tucker

http://www.w3.org/2001/XMLSchema#string

Kelly J Hunt

http://www.w3.org/2001/XMLSchema#string

Maria F Lopes-Virella

http://www.w3.org/2001/XMLSchema#string

Mohammad R Mataria

http://www.w3.org/2001/XMLSchema#string

Nishant M Bhensdadia

http://www.w3.org/2001/XMLSchema#string

Veterans Affairs Diabetes Trial (VADT) study group

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial

A statistical model for identifying proteins by tandem mass spectrometry

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15).

Association of haptoglobin with sodium sensitivity and resistance of blood pressure.

Proteomic discovery of diabetic nephropathy biomarkers.

Observation on renal outcomes in the Veterans Affairs Diabetes Trial

Early renal function decline in type 2 diabetes.

P2888

P304

1136-1143

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/KI.2013.57

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P50

Michael G. Janech

P577

2013-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236087589

http://www.w3.org/2001/XMLSchema#string

P698

23536133

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3672380

http://www.w3.org/2001/XMLSchema#string